Mechanisms of Immunity in Post-Exposure Vaccination against Ebola Virus Infection
Fig 1
Post-exposure VLP treatment protects mice from EBOV infection.
(A) Mice were infected i.p. with ~1,000 pfu mouse-adapted EBOV virus and 24 hours later were treated i.p. with 50 ug EBOV VLPs (GP+NP+VP40), Marburg VLP, or left untreated. EBOV-VLP-treated mice survived, whereas Marburg VLP-treated mice did not survive, and did not have delayed time-to-death compared to untreated mice. n = 10 for eVLP and mVLP; n = 20 for no VLP. (B) Mice were infected with EBOV and treated i.p. with different doses of EBOV VLPs 24 hours post-infection. n = 10. (C) Mice were infected with EBOV and treated intramuscularly with different doses of VLPs 24 hours post-infection. Less protection was seen with i.m. injection than i.p. treatment at lower doses. n = 10. (D) VLPs made from VP40 alone or VP40+NP did not protect mice when given i.p. 24 hours post-exposure. VLPs made from VP40+GP had some protection, but less than the trivalent VP40+GP+NP. n = 20 for VP40; n = 29 for VP40+NP; n = 20 for GP+NP+VP40.